San Diego-based Viking Therapeutics marked by itself as a serious competitor within the weight loss drug market in February following revealing promising facts from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection As well as in March the company